Key Takeaways
- A UCSF study showed that psilocybin reduces inflammation and mitochondrial stress in Parkinson’s patients, marking a significant advance in research.
- Researchers tracked a proinflammatory index and mitochondrial stress markers, finding significant drops after psilocybin doses.
- Psilocybin therapy could improve not only mood but also physical symptoms in patients with neurodegenerative diseases.
- Experts emphasize that larger trials are needed to confirm these findings and explore the potential for psilocybin in treating other inflammatory conditions.
Researchers at the University of California, San Francisco published a research letter in JAMA Psychiatry last month, examining how psilocybin affects inflammation and mitochondrial stress in people with Parkinson’s disease and mood dysfunction. Twelve participants completed the trial, and blood samples from nine of them were analyzed at four points: before treatment, one day after a 10-mg dose, one day after a 25-mg dose, and 30 days after the final dose.
The study tracked a proinflammatory index built from five markers: interleukin-6, interleukin-8, tumor necrosis factor alpha, interferon gamma, and C-reactive protein. That index dropped significantly at every follow-up point, including a month after the last psilocybin session. The team also measured growth differentiation factor 15, a marker of cellular stress linked to mitochondrial dysfunction, which fell notably one day after each dose.
Dr. Ellen Bradley, an associate professor of psychiatry at UCSF who helped lead the analysis, called the findings “an initial biological signal to investigate” told NPR. It’s a modest sample size, but it marks one of the first times researchers have tracked these biological markers in people, rather than relying only on animal or cell studies.
How Researchers Measured Inflammation and Mitochondrial Stress
Participants in the trial had mild to moderate Parkinson’s disease and were given oral doses of synthetic psilocybin, 10 mg followed roughly two weeks later by 25 mg. Blood draws captured changes in inflammatory cytokines along with two mitokines, GDF-15 and FGF-21, that signal how stressed the body’s energy-producing mitochondria are.
The proinflammatory index fell by a standardized mean difference of 0.72 one day after the 10-mg dose and remained lower a month after the 25-mg dose. GDF-15 dropped meaningfully after each dosing session as well, though it returned closer to baseline by the 30-day mark. FGF-21 trended upward but didn’t reach statistical significance.
This is important because Parkinson’s disease is already associated with elevated inflammation and mitochondrial stress, both of which are thought to contribute to the condition’s motor and mood symptoms. Seeing these markers shift after psilocybin treatment gives researchers a concrete biological thread to follow, something that’s been largely missing from psychedelic research involving people with neurodegenerative conditions.
Why These Findings Matter for Parkinson’s Disease
This study builds on an earlier pilot trial the same UCSF team published in 2025 in Neuropsychopharmacology, which found that psilocybin therapy was associated with improvements in depression and motor function among Parkinson’s patients. People with neurodegenerative diseases are typically excluded from psychedelic trials due to safety concerns, so this research fills a real gap.
Inflammation and mitochondrial stress are believed to play a role in how Parkinson’s disease progresses and how symptoms like mood dysfunction show up. If psilocybin can meaningfully calm those processes, it opens a possible explanation for why participants in the earlier trial reported feeling better, not just in mood but in physical symptoms too.
Researcher D. Parker Kelley of Columbia University, a co-author on the paper, told NPR the results could point to something larger than Parkinson’s disease alone. “It’s a potential jumping off point for a lot more research in this area,” he said, noting possible relevance to depression, anxiety, and cardio-metabolic or inflammatory disorders more generally.
That said, this remains early-stage work. The sample size was small, there was no placebo control group, and participants knew they were receiving psilocybin, all of which limit how much can be concluded right now.
What the Experts Are Saying
Charles Nichols, a pharmacology professor at LSU Health Sciences Center who wasn’t involved in the study, has spent roughly 15 years studying psilocybin’s anti-inflammatory effects in lab models. His team discovered years ago that certain psychedelics acted as potent anti-inflammatory agents in cell cultures simulating blood vessel inflammation, even at doses well below what causes psychoactive effects.
Nichols called the new human data “really exciting” and said it validates much of the lab work his group and others have done on psychedelics’ anti-inflammatory and mitochondria-protective properties. Since his original discovery, his lab has tested psychedelics in animal models of asthma, arthritis, and cardiovascular disease, but confirming these effects translate to humans has remained the missing piece.
Aoife O’Donovan, a UCSF psychiatry professor and co-author on the study, pointed out that the blood marker changes represent objective data rather than self-reported symptoms. She noted this gives the research team confidence to pursue follow-up studies, even while acknowledging that larger, controlled trials are needed before drawing firm conclusions about psilocybin’s anti-inflammatory potential.
What This Means for Future Psychedelic Research
This study won’t settle the debate on psilocybin’s medical potential, but it adds a genuine data point to a growing body of evidence. For years, researchers have shown in petri dishes and animal models that psychedelics can calm inflammatory responses and ease mitochondrial stress. Now there’s human data pointing the same direction, specifically in a population dealing with a disease where inflammation is already a known problem.
Future research will need bigger groups, placebo controls, and longer follow-up periods to see whether these changes hold up and whether they translate into lasting clinical benefits. Researchers are also interested in whether similar effects might show up in other inflammatory conditions beyond Parkinson’s disease, including depression, anxiety, and metabolic disorders.
For now, the takeaway is cautiously optimistic. Psilocybin appears to do more than shift mood and perception. It may also influence how the body manages inflammation and cellular stress, and that’s a thread worth pulling on.
Frequently Asked Questions
The JAMA Psychiatry study found that psilocybin was linked to significantly lower levels of inflammatory markers in people with Parkinson’s disease, with reductions lasting up to 30 days after the final dose.
Researchers measured GDF-15, a marker of mitochondrial stress, and found it dropped significantly one day after each psilocybin dose, though the effect faded somewhat by the 30-day follow-up.
Yes. The trial enrolled 12 participants with mild to moderate Parkinson’s disease and mood dysfunction, with blood samples from nine participants analyzed for inflammatory and mitochondrial markers.
The study had a small sample size, no placebo control group, and participants knew they were receiving psilocybin. Researchers say larger, controlled trials are needed to confirm the findings.
Researchers involved in the study believe the findings could have relevance beyond Parkinson’s disease, potentially extending to depression, anxiety, and cardio-metabolic or inflammatory disorders, though this hasn’t been directly tested yet.
